Search Results - live-attenuated

3 Results

Sort By:

Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene

RSV is the most important viral agent of severe respiratory disease in infants and young children worldwide and also causes substantial morbidity and mortality in older adults. RSV is estimated to cause more than 33 million lower respiratory tract illnesses, three million hospitalizations, and nearly 200,000 childhood deaths worldwide annually, with...

Published: 7/25/2024 | Inventor(s): Cyril Le Nouen, Ursula Buchholz, Peter Collins

Keywords(s): ADDITIONAL, BEARING, Codonpair, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deoptimized, DXXXXX, GENES, Improved, Live-Attenuated, M, Mutations, N, NS1, NS2, P, Pgene, POINT, respiratory, RSV, SH, Syncytial, Vaccine, virus

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease

Chimeric Dengue/Zika Viruses for Live-Attenuated Zika Vaccine Development

Zika virus (ZIKV) can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause microcephaly and other severe birth defects. Currently, there are no vaccines to prevent or medications to treat Zika infections. CDC engineered chimeric Zika viruses on the dengue virus (DENV) sub-type 2 (D2) PDK-53 vaccine backbone (D2 PDK-53)...

Published: 7/25/2024 | Inventor(s): Claire Kinney

Keywords(s): chimeric, Dengue/Zika, Development, Live-Attenuated, NCEZID-DVBD, Vaccine, Viruses, VLXXXX, WBXXXX, WIXXXX, WNXXXX, XEXXXX, XKXXXX, YAXXXX, YBXXXX, Zika

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Vaccines, Application > Research Materials

Multivalent Vaccines for Rabies Virus and Filoviruses

No vaccine candidates against Ebola virus (EBOV) or Marburg virus (MARV) are nearing licensure and the need to develop a safe and efficacious vaccine against filoviruses continues. Whereas several preclinical vaccine candidates against EBOV or MARV exist, their further development is a major challenge based on safety concerns, pre-existing vector immunity,...

Published: 7/25/2024 | Inventor(s): Jason Paragas, Reed Johnson, Peter Jahrling, Joseph Blaney

Keywords(s): Against, Bivalent, Confer, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, DDXXXX, Dual, DXXXXX, Ebola, Ebola virus disease, INACTIVATED, Live-Attenuated, Marburg hemorrhagic fever, Protection, rabies, That, UAXXXX, vaccines, Viruses

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials, TherapeuticArea > Rare / Neglected Diseases